Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A major study of 120,000+ older adults found that nitrogen-containing bisphosphonates (NBPs) — common osteoporosis drugs — were linked to up to a 24% lower risk of Alzheimer's and other dementias. Researchers at the University of Hong Kong say the findings suggest these widely available, affordable medications could offer a dual benefit: stronger bones and a healthier brain. More research is needed to confirm a direct cause-and-effect relationship.
Could your bone medication also be protecting your brain? A large observational study from the University of Hong Kong (HKUMed), published in Alzheimer's & Dementia, found that older adults taking nitrogen-containing bisphosphonates (NBPs) — drugs like alendronate and zoledronate commonly prescribed for osteoporosis — had a significantly lower risk of developing Alzheimer's disease and related dementias (ADRD).
The study analyzed electronic health records of over 120,000 patients aged 60 and older in Hong Kong between 2005 and 2020. NBP users had a 16% lower dementia risk compared to those on no osteoporosis medication, and a 24% lower risk compared to those on other osteoporosis treatments. Women and patients with prior hip fractures showed especially strong associations. Because this is an observational study, a direct causal link has not been established.
By the Numbers:
Why it matters: With dementia cases set to nearly triple by 2050 and newer Alzheimer's therapies remaining costly and limited in access, repurposing affordable, already-approved drugs like NBPs could be a meaningful option for high-risk aging populations — particularly those already being treated for osteoporosis.
